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Foot-and-mouth disease virus (FMDV) causes a highly contagious infection in cloven-hoofed animals. The format of
FMD virus-like particles (VLP) as a non-replicating particulate vaccine candidate is a promising alternative to
conventional inactivated FMDV vaccines. In this study, we explored a prokaryotic system to express and assemble
the FMD VLP and validated the potential of VLP as an FMDV vaccine candidate. VLP composed entirely of FMDV
(Asia1/Jiangsu/China/2005) capsid proteins (VP0, VP1 and VP3) were simultaneously produced as SUMO fusion
proteins by an improved SUMO fusion protein system in E. coli. Proteolytic removal of the SUMO moiety from the
fusion proteins resulted in the assembly of VLP with size and shape resembling the authentic FMDV. Immunization
of guinea pigs, swine and cattle with FMD VLP by intramuscular inoculation stimulated the FMDV-specific antibody
response, neutralizing antibody response, T-cell proliferation response and secretion of cytokine IFN-γ. In addition,
immunization with one dose of the VLP resulted in complete protection of these animals from homologous FMDV
challenge. The 50% protection dose (PD50) of FMD VLP in cattle is up to 6.34. These results suggest that FMD VLP
expressed in E. coli are an effective vaccine in guinea pigs, swine and cattle and support further development of
these VLP as a vaccine candidate for protection against FMDV.Introduction
Foot-and-mouth disease (FMD) is an acute, highly con-
tagious viral disease, which may cause severe economic
losses in susceptible cloven-hoofed animals [1,2]. In
1997 an FMD outbreak was reported in Taiwan which
had been free of the disease for 68 years. This devasta-
ting outbreak resulted in the slaughter of more than 4
million pigs, almost 38% of the entire pig population, at
a cost of approximately U.S. $6 billion [3]. In 2001 a* Correspondence: shiqisun21@hotmail.com; hnxiangtao@hotmail.com;
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reproduction in any medium, provided the orlarge FMD outbreak started in the United Kingdom [4]
and spread to France, Ireland and The Netherlands. The
losses to agriculture in the United Kingdom alone were
about £3.1 billion [5]. These outbreaks have significantly
increased public awareness of this highly infectious dis-
ease and highlight the importance of disease control, in-
cluding regular vaccination and slaughter of infected
and contact animals, in endemic areas [6,7]. Although
the conventional inactivated FMDV vaccine has been ex-
tremely successful in reducing the number of disease
outbreaks in many parts of the world where the disease
is enzootic, there are a number of concerns and limita-
tions with its use in emergency control programs.
Among these concerns and limitations, safety issues
such as the possibility of virus escape during vaccine
production and through insufficient chemical inactiva-
tion of virus highlight the need for the development of
new generation vaccines.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recognized as safe, effective vaccine candidates for viral
diseases [8]. VLP are virus-sized particles with the
supra-molecular structures that have the form of rods or
icosahedrons [9]. They are composed of multiple copies
of one or more recombinant expressed viral structural
proteins which spontaneously assemble into particles
without incorporation of the viral genome. They display
antigens in an ordered and repetitive way, thus inducing
rapid, robust humoral immune responses as well as effi-
cient T-cell responses [10]. Because VLP combine many
of the advantages of whole virus vaccines and recombi-
nant subunit vaccines into one system, two VLP vac-
cines, including the papillomavirus vaccine and the
hepatitis B virus vaccine, are already licensed for use in
humans, and a number of other VLP vaccines are being
tested [8]. Many attempts have also been made to pro-
duce FMD VLP in a variety of hosts. The VLP-based
FMD vaccines produced in baculovirus/insect cells,
baculovirus/silkworm larvae, and by a replication-
deficient human adenovirus vector-based system are two
of the successful recombinant vaccine candidates in
protecting the target species (cattle or swine) against
FMDV challenge [11-20]. The FMD VLP vaccine candi-
date produced by the deficient adenovirus is currently
being manufactured in experimental batches and tested
in cattle in the US mainland (for the first time in US his-
tory) as part of the veterinary licensing process [20]. Lee
et al. reported the VLP produced in bacteria [21]. How-
ever, the immunogenicity of this VLP has not been eva-
luated. Compared with eukaryotic expression systems,
such as insect and mammalian cells, expression of hete-
rologous genes in bacteria is by far the simplest and
most inexpensive means available for research or com-
mercial purposes. However, only > 20% of heterologous
genes expressed in E. coli render soluble or correctly
folded proteins [22]. In order to improve the expression
efficiency of heterologous proteins in E. coli, many mo-
difications have been made, including the development
of strong promoters [23], coexpression with chaperones
[24] and use of protein fusions. Among them, expression
of the recombinant proteins such as fusion proteins, es-
pecially for difficult-to-express proteins, is one of the
most effective ways in improving the solubility of recom-
binant proteins. Several gene-fusion systems, such as
NusA, maltose binding protein (MBP), glutathione-S
-transferase (GST), ubiquitin (UB), and thioredoxin (Trx),
have been developed [25,26]. These fusion proteins are
frequently employed to enhance protein expression and to
facilitate purification [27-29]. Recently, small ubiquitin-
like modifier (SUMO) protein, a ubiquitin-related protein,
has emerged as an effective biotechnological tool, since
SUMO usually promotes correct folding and structural
stability of the fusion proteins, leading to enhancedfunctional production of the partner proteins compared to
its untagged version [30].
The FMDV genome is a positive-sense, single-stranded
RNA with one large open reading frame. Its translation
yields a polyprotein that is subsequently processed by
virus-encoded proteases to produce structural and non-
structural proteins necessary for virus assembly and rep-
lication. One of the initial polyprotein cleavage events,
mediated by the 2A protein, is co-translational cleavage
at the N terminus of the 2B protein. The P1-2A precur-
sor is processed by a viral 3C protease to produce the
structural proteins VP0, VP1 and VP3. These proteins
can then self-assemble to form icosahedral empty capsid
particles [31-33], which consist of 60 copies of each pro-
tein. Many attempts have been made to produce FMDV
capsid protein(s) and subsequently assemble into VLP in
eukaryotic expression systems by combining the P1-2A
and 3C, in order to assemble virus capsids correctly
[12,34]. However, this strategy has not been achieved in
prokaryotic expression systems, especially in E. coli. To
overcome this technical bottleneck, we recently developed
an improved SUMO fusion protein system in E. coli
according to previous research [21] and produced several
water-soluble virus capsid proteins. Fusion proteins of
three FMDV capsid proteins, VP0, VP1 and VP3, were effi-
ciently expressed by the SUMO expression system in
E. coli. After removal of the SUMO moiety from the
fusion proteins, the three capsid proteins could be as-
sembled into VLP with size and shape resembling the
authentic FMDV. These VLP were prepared and used
as an immunogen in guinea pigs, swine and cattle.
The data show that FMDV-specific antibodies, neu-
tralizing antibodies, T-cell proliferation and secretion
of IFN-γ were efficiently induced in the immunized
animals. Furthermore, the immunized animals were
totally protected against challenge with FMDV after
inoculation with one dose of the VLP. These results
encourage further work towards the development of a
VLP vaccine against FMDV.
Materials and methods
Cells and virus
BHK-21 cells were cultured at 37°C in a 5% CO2 atmos-
phere in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Invitrogen corporation, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS; HyClone
Laboratories Inc., Victoria, Australia), 100 U/mL penicillin
and 100 mg/mL streptomycin. FMDV strain Asia1/Jiangsu/
China/2005 (GenBank accession number: EF149009) was
propagated in BHK21 cells.
Plasmid constructions
A SUMO fusion protein expression vector was constructed
as described previously with modification [35]. This vector
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gene (KanR). A pSMA vector that carries an ampicillin re-
sistant gene (AmpR) and a pSMC vector that carries
a chloramphenicol resistant gene (ChlR) were
constructed by replacing KanR of the pSMK vector
with AmpR and ChlR, respectively. Three FMDV cap-
sid proteins VP0, VP1 and VP3 were amplified by
polymerase chain reaction (PCR), subcloned into pSMK,
pSMA and pSMC respectively. The recombinant plasmids
were designated as pSMKVP0, pSMAVP1 and pSMCVP3
respectively.
Protein production
To simultaneously express the three SUMO fusion pro-
teins in the same E. coli cells, pSMKVP0, pSMAVP1 and
pSMCVP3 were transformed into E. coli BL21(DE3)
(Stratagen, La Jolla, CA, USA) simultaneously and se-
lected by Amp, Kan and Chl resistance. Expression, puri-
fication and proteolytic cleavage of His6-Smt3 fusion
proteins were carried out as described before [35]. The
expressed proteins were analyzed by 10% sodium
dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) under denaturing conditions and the speci-
ficity of the proteins was confirmed by immunoblot
assay [12].
VLP quantification
A sucrose gradient ultracentrifugation method was used
for analytical purpose as previously described [31].
Briefly, the proteolytically cleaved protein or inactivated
virus was layered on the top of a 10%–30% (w/v) sucrose
gradient in NET buffer (0.1 M NaCl, 0.001 M EDTA,
0.05 M Tris–HCl, pH 7.5). The samples were then
centrifuged at 35 000 rpm for 3 h using an Optima
L-100 XP ultracentrifuge (Beckman Coulter, Fullerton,
CA, USA). After centrifugation, the gradients were frac-
tionated and the optimal density (OD) at 280 nm or
260 nm of each fraction was measured using UA-Visible
Spectrophotometer BioMate 3S (ThermoFisher Scientific
Inc. Madison, WI, USA) and the quantity of intact capsids
was determined. The fraction was used for electron
microscopy.
Electron microscopy observation of VLP
Samples for transmission electron microscopy (TEM)
measurements were prepared by dipping a drop of the
purified protein complex onto Formvar coated copper
grids (300 mesh, Pelco, CA, USA) at room temperature.
The grid was then removed, and excess liquid was
drained off by blotting the edge of the grid with a piece
of clean filter paper. Next, the grid was floated on a drop
of 2% phosphotungstic acid (pH 6.5) for 1 min and air-
dried for a few minutes after the excess phosphotungstic
acid was removed as before. TEM images were recordedon a JEOL 2010 transmission electron microscope ope-
rated at an acceleration voltage of 100 kV.
Animal immunization and challenge protocols
Fifteen guinea pigs weighing 400–500 g were obtained
from the laboratory animal center of Lanzhou veterinary
research institute, China. All the animals were fed in an
isolated hutch. The guinea pigs were randomly divided
into three groups of 5 animals each: group A, inactivated
FMDV serotype Asia1; Group B, FMD VLP; Group C,
phosphate buffered saline (PBS, pH 7.4). The guinea pigs
were injected with 0.2 mL inactivated FMDV or 50 μg
FMD VLP together with unassembled proteins emulsi-
fied by freund complete adjuvant or 0.2 mL PBS in the
tibialis cranialis muscle of both rear legs. The serum
samples were taken from the heart at 28 days post-
immunization (dpi) after guinea pigs were anesthetized
with pentobarbital sodium. All guinea pigs were sub-
cutaneously and intradermally challenged with 0.2 mL
100 times 50% infective dose (100 ID50) per guinea pig
of homologous live virus on left back sole at 28 dpi. All
guinea pigs were kept in an isolated hutch and examined
for 7 days. The lesion appearing only on the left back
sole was referred to as an indicator of partial protection,
on both back soles as an indicator of no protection and
no lesion on the back was considered as an indicator of
total protection.
Thirteen 2-month-old pigs, sero-negative for FMDV,
were purchased from a conventional breeding/finishing
farm. All animals were housed in an animal biosafety
level 3 (ABSL3) facility and divided into three groups.
There are five pigs in Group A and Group B, three pigs
in Group C. Group A: Inactivated FMDV serotype Asia1
(2 mL); Group B: FMD VLP (50 μg); Group C: PBS
(2 mL). FMDV inactivated vaccine or FMD VLP were
emulsified with the adjuvant Montanide ISA 206
(Seppic, Paris, France) with a ratio of 1:1. All pigs were
intramuscularly inoculated at the ear-root-neck area and
bled at 10, 18 and 28 dpi. Four weeks after vaccination,
all pigs were challenged by direct inoculation at the ear-
root-neck area with the virulent homologous virus strain
Asia1/Jiangsu/China/2005 at 1000 ID50 per pig. All pigs
were housed in an isolated facility and examined for
10 days after challenge. The animals were examined
daily for clinical signs of FMD, including the appearance
of vesicles on the mouth and feet. Any lesion on the
snot and feet of pigs was referred to as an indicator of
no protection.
Seventeen one-year old cattle, sero-negative of FMDV,
were divided into four groups. Group A: one dose of
FMD VLP; Group B: 1/3 dose of FMD VLP; Group
C: 1/9 dose of FMD VLP; Group D: Healthy control.
Except for Group D which included 2 cattle, other
groups included 5 animals each. All animals were
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intramuscular inoculation of FMD VLP emulsified
with the adjuvant Montanide ISA 206 with the ratio
of 1:1. One dose contains 50 μg FMD VLP. Fifty per-
cent protection dose (PD50) test was performed as de-
scribed by the OIE to test the potency of FMD VLP
as a vaccine candidate. Vaccinated and control cattle
were challenged by tongue intradermal inoculation
with a homologous virus strain Asia1/Jiangsu/China/
2005 at 10 000 ID50 per head. The animals were peri-
odically inspected for possible occurrence of lesions
in the mouth, tongue, lips, buccal mucosa, teats, and
feet. Any lesion at a site in the mouth other than the
inoculation site within 10 days post-challenge (dpc)
was considered as a rupture of immunity and consi-
dered as no protection. Blood and serum samples were
collected by standard protocols at 9, 16, 21 dpi and 2, 5,
8, 10 dpc. The bovine PD50 content of the vaccine was
calculated based on the Reed-Muench method from
each animal protected in each group.
Ethics statement
All animals received humane care in compliance with
good animal practice according to the Animal Ethics
Procedures and Guidelines of the People's Republic of
China. The specific experiments were approved by
Animal Ethics Committee of Lanzhou Veterinary Research
Institute, Chinese Academy of Agricultural Sciences
(permit number LVRIAEC2011-018).
Western blot analysis of animal serum
BHK-21 cells in serum-free DMEM were infected with
FMDV type Asia1/Jiangsu/China/2005 at a multiplicity
of infection of 10 and incubated for several hours at
37°C with 5% CO2 until a cytopathic effect (CPE) was
observed by light microscopy. Cells uninfected and
infected with FMDV Asia1/Jiangsu/China/2005 were
harvested and frozen-thaw for three times. 5 × SDS
loading buffer was added in cell lysates and boiled for
10 min. The specificity of animal serum against whole
virus or VLP was confirmed by immunoblot assay
using sera obtained from animals unvaccinated or
vaccinated with inactivated FMD vaccine and VLP
vaccine, respectively.
Determination of antibody titers by ELISA
The antibody titers in immunized guinea pigs were
determined by indirect-ELISA as described elsewhere
[36,37]. Briefly, 96-well plates were coated with
inactivated FMDV Asia1/Jiangsu/China/2005 (100 mL/
well) in 0.05 M bicarbonate buffer (pH 9.6) at 4°C over-
night. After binding of the target antigen, wells were
blocked in 100 μL PBST containing 1% BSA at 37°C for
1 h, washed and drained. One-hundred fold dilutions ofsample sera were added to the microtiter wells in 50 μL
of PBST-BSA and incubated for 1 h at 37°C. After the
sample sera were removed and washed. Horseradish per-
oxidase (HRP)-conjugated anti-guinea pig antibody
(1:2000) (Sigma, St. Louis, MO, USA) was added and
incubated for 1 h at 37°C. Then the enzyme substrate
o-phenylenediamine (OPD, Sigma, St. Louis, MO, USA)
in 50 μL sodium citrate was added to each well and in-
cubated for 15 min at room temperature. The reaction
was stopped with 50 μL 2 M H2SO4, and the plate was
read at 492 nm on a spectrophotometer (BioRad,
Hercules, CA, USA). Antibody reactivity was reported as
OD values.
The FMDV-specific antibody titers in immunized pigs
and cattle were detected by a liquid-phase-block ELISA
(LPB-ELISA) kit as described by Shao et al. [38]. Briefly,
50 μL of 2-fold serial dilution of each test serum in
duplicate were prepared in U-bottom multiwell plates
(Corning, NY, USA). To each well, 50 μL of a constant
dose of viral antigen that was used to raise the rabbit
antiserum for coating the plates were added and left at
4°C overnight. Subsequently, 50 μL of the serum-antigen
mixture were transferred to an ELISA plate pre-coated
with rabbit anti-FMDV serum and incubated at 37°C for
1 h at a dilution of 1:1000. After thorough washing with
PBST, 50 μL of guinea-pig antiserum was added to each
well and the plates were incubated at 37°C for 1 h. The
plates were washed five times with PBST, followed by
the addition of 50 μL of rabbit anti-guinea pig IgG-HRP
at a dilution of 1:2000 (Sigma) and incubated at 37°C for
1 h. Then, the enzyme substrate o-phenylenediamine
(Sigma) was added to each well for 10 to 15 min of incu-
bation after being washed and drained. The reaction
was terminated with 2 M H2SO4, and the plate was read
at 492 nm on a spectrophotometer (BioRad, Hercules).
Antibody titer was reported as log10 of the reciprocal of
the highest dilution.
Serum neutralization assay
Serum samples collected from animals at different time
points were heat-inactivated (30 min, 56°C) and used in
a microtiter neutralization assay on BHK-21 cells. Serial
dilutions of serum were incubated with 100 TCID50 of
FMDV strain Asia1/Jiangsu/China/2005 at 37°C and 5%
CO2 for 1 h, followed by infection of monolayers of
BHK-21 cells in 96-well plates for 72 h. Thereafter, the
cells were examined for FMDV-specific cytopathic effect
and neutralization titers were calculated as log10 of the
reciprocal of the highest dilution resulting in 50%
neutralization [36].
Lymphocyte proliferation assay
The T-lymphocyte proliferation assay was performed
with the Cell Titer 96AQueous Non-Radioactive Cell
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guinea pigs from each group were sacrificed and single
lymphocyte suspensions were prepared from spleens at
28 dpi as described previously [36,37]. Peripheral blood
mononuclear cells (PBMC) were isolated from pigs at 28
dpi or cattle at 21 dpi by centrifugation in Ficoll-Paque
Plus (density 1.077; Amersham Biosciences, Corston,
UK) at room temperature for 30 min. Mononuclear cells
were collected from the buffy coat and centrifuged, and
residual red blood cells were lysed by incubation in water
for 1 min followed by the addition of Eagle’s solution.
After two washes in PBS, the cells were resuspended in
RPMI 1640 supplemented with 25 mM HEPES, 2 mM
glutamine, 10% FBS, penicillin/streptomycin. Lymphocyte
suspensions of spleen or PBMC were added to 96-
well flat-bottomed plates at a concentration of 100 μL
per well (2 × 105 cells per well). Subsequently, 100 μL
per well of medium with or without inactivated FMDV
Asia1/Jiangsu/China/2005 (10 μg/mL) was added and
mixed. Each sample was tested in triplicate. Phytohaem-
agglutinin (PHA) (Sigma) at the final concentration of
10 μg/mL was used as a positive control. The plates
were incubated at 37°C for 60 h followed by incuba-
tion with a tetrazolium compound [3-(4,5-dimethyl-2-
yl) -5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS] and then incubated
at 37°C under 5% CO2 for 4 h. The absorbance at
490 nm was measured with a spectrophotometer
(BioRad, Hercules, CA, USA). Data are expressed as
stimulation index (SI), calculated as the mean reading
of triplicate wells of antigen-stimulated cells divided
by the mean reading of triplicate wells from unstimu-
lated (negative control) wells.
Analysis of cytokine IFN-γ
Spleen lymphocyte or PBMC supernatants were cultured
with 10 μg/mL of inactivated FMDV Asia1/Jiangsu/
China/2005 for 72 h and analyzed for cytokine IFN-γ
expression using commercially available guinea pig, por-
cine, bovine IFN-γ ELISA kits (Uscn Life Science,
Wuhan, China) by following the instructions supplied.
The concentration of IFN-γ in the samples is then deter-
mined by comparing the O.D. of the samples to the
standard curve.
Virus infectivity assay
The presence of virus in serum was determined by a
standard plaque assay on BHK-21 cells. Briefly, confluent
monolayers of cells on six-well plates were adsorbed
with serial dilutions of serum samples. Following adsorp-
tion at 37°C for 1 h, the samples were removed and cells
were washed twice with PBS (pH, 7.4). Then, 2 mL of
DMEM containing 1% agarose gel were added and incu-
bated at 37°C in a humidified atmosphere containing 5%CO2 for 24 h. Cells treated with samples were stained
with a neutral red solution to visualize the plaques. Virus
titers were expressed as log10 PFU per mL.
Detection of FMDV RNA by real time RT-PCR
Frozen serum samples from animals were thawed and
processed for RNA extraction and measurement of spe-
cific FMDV RNA by real-time reverse transcription-PCR
(RT-PCR) as previously described. Real time RT-PCR
was performed using a Mx3005P sequence detection sys-
tem (Agilent, Santa Clara, CA, USA). Samples were con-
sidered negative when FMDV RNA molecules/mL were
less than 103 [39,40].
Statistical analysis
Data are presented as mean ± SD. The statistical analysis
was first performed to verify the homogeneity of variance
by using the Levene test. Then, the analysis of variance
between groups using One-way ANOVA was applied.
Finally, a comparison of mean pair wise differences be-
tween groups using Least Significance Difference (LSD)
was performed. Significance of all statistical tests was
set at 0.05 (p < 0.05).
Results
Construction and expression of soluble His6-SM FMDV
capsid proteins
Three components of the structural proteins of FMDV,
VP0, VP1 and VP3, cleaved from the P1 protein precur-
sor, can remain associated in a protein complex and act
as a monomer for the self-assembly of five monomers
into the pentameric capsid subunit. Further assembly of
12 pentamers and a molecule of genomic RNA generates
a provirion [41,42], which subsequently undergoes ma-
turation cleavage to convert VP0 into VP2 and VP4 to
produce the mature infectious virion [43-45]. How-
ever, FMDV has the ability to form empty capsids
sharing the same antigenicity as virions, but does not
contain RNA and cleaved VP0 [46-48]. To express
the three structural proteins and to further facilitate
the assembly of FMD VLP, recombinant plasmids en-
coding VP0 (pSMKVP0), VP1 (pSMAVP1) and VP3
(pSMCVP3) were constructed. These three vectors ex-
pressing SUMO fusion proteins were simultaneously
transformed and induced to express in the same E. coli
host cells. As shown in Figure 1A, the three SUMO fusion
proteins were all strongly induced by IPTG and were
water-soluble. The expression efficiency was further im-
proved by incubation at 16°C overnight, compared with
the conditions at 37°C for 3–4 h (data not shown). The
yield of the purified protein produced by the recombinant
bacterial clone varied between 15–20 mg/L culture, which
is significantly higher than the purified protein produced
by the scheme described previously [21]. The molecular
Figure 1 Expression and assembly of purified FMDV capsid proteins. (A) SDS-PAGE (left panel, lanes M, 1–4) and Western blot (right panel,
lanes 5–8) analysis of the purified capsid protein complexes without Ulp1 protease treatment, including the SUMO-tagged FMDV VP3 protein
expressed individually (lanes 1 and 8), the SUMO-tagged FMDV VP1 protein expressed individually (lanes 2 and 7), the SUMO-tagged FMDV VP0
protein expressed individually (lanes 3 and 6) and the three SUMO-tagged protein complex simultaneously expressed (lanes 4 and 5).
(B) SDS-PAGE (lane 1) and Western blot (lane 2) analysis of the purified three SUMO-tagged protein complex after protease digestion and the
second affinity chromatography. (C) Purification and analysis of FMD VLP by sucrose gradient ultracentrifugation. The purified three capsid
proteins were loaded onto a 10%–30% (w/v) sucrose gradient. After centrifugation, 20 fractions were collected and measured at 280 nm using
UA-Visible Spectrophotometer BioMate 3S (ThermoFisher Scientific Inc. USA) and the quantity of capsid proteins in each fraction was determined
and plotted. (D) Negative staining electron microscopy of FMD VLP containing purified VP0, VP3 and VP1. Scale bar, 100 nm.
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fusion protein are approximately 45, 35 and 36 kDa, re-
spectively (Figure 1A). So, the latter two protein bands
were not well separated (Figure 1A, lane 4 and 5).
Extracts containing the coexpressed SUMO fusion
proteins were purified on a Ni2
+-resin and then treated
with SUMO protease to remove the His6-Sm moieties.
The cleavage products contained three water soluble
polypeptides with molecular weights about 33 kDa
(VP0), 24 kDa (VP3) and 23 kDa (VP1) and His6-Sm
tag, respectively, upon examination by SDS-PAGE (data
not shown). After purification of the cleavage products
by Ni2
+-resin again, the three fusion proteins were left in
solution (Figure 1A).
VLP assembly and quantification
To demonstrate if the expressed FMDV capsid proteins
could assemble into empty particles, the proteolytically
cleaved proteins were analyzed by sedimentation on a
10%–30% sucrose gradient. Fractions were collected
and measured with a spectrophotometer. The results
(Figure 1C) show the presence of a peak correspon-
ding to 75S empty capsid particles from FMDV
[12,31]. The peak fractions were pooled and the percentage
of VLP was calculated from the peak area. This portionwas approximately 43% of the total expressed proteins
(Figure 1C), while the other 57% of proteins failed to
assemble into stable empty capsids, as they remained
near the top of the gradient (Figure 1C).
Transmission electron microscopy was then used to
examine the extent of VLP assembly by these ternary
protein complexes. As shown in Figure 1D, the VP0-VP1
-VP3 complexes formed uniform round VLP aggregates
with a diameter about 25 nm, which is similar to the
average diameter of 25 nm of the authentic FMDV
particles.
Immunization with FMD VLP induces specific protective
responses in guinea pigs
Guinea pigs are one of the ideal experimental animals for
FMDV study and widely used for initial characterization
of the antigenic properties of FMD vaccine candidates. To
determine if FMD VLP could stimulate anti-FMDV im-
mune responses in guinea pigs, groups of five guinea pigs
were immunized with FMD VLP intramuscularly and two
other groups of five animals were immunized with
inactivated FMDV as a positive control and PBS as a nega-
tive control, respectively. The results show that FMDV-
specific antibodies, neutralizing antibodies, specific T-cell
response and IFN-γ responses were efficiently induced by
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observed between guinea pigs inoculated with PBS and
with either FMD VLP or FMD inactivated vaccine, how-
ever, no significant difference was found between guinea
pigs inoculated with the FMD VLP and FMD inactivated
vaccine.
After challenge with 100 ID50 FMDV Asia1/China/
Jiangsu/2005 per guinea pig, all of the control animals
inoculated with PBS showed typical symptoms on both
back feet at 2 dpc, as expected. In contrast, none of the
guinea pigs vaccinated with the inactivated FMD vaccine
and the FMD VLP developed any symptom associated
with FMDV replication.
Immunization with FMD VLP induces specific protective
responses in pigs
The efficiency of FMD VLP as a potent FMD vaccine
candidate in guinea pigs prompted us to investigate the
effectiveness of FMD VLP as a vaccine in pigs, one of
the natural hosts of FMDV [49]. The FMDV-specific
antibody responses were quantified by LPB-ELISA in
pigs inoculated with FMD VLP. Compared to the con-
trol group inoculated with PBS, the presence of specific
antibodies was detected at 10 dpi in all inoculated ani-
mals, and the level of specific antibodies increased and
remained at a high level until 28 dpi (Figure 2A). FMDV-
specific neutralizing antibodies were found in sera from
pigs inoculated with the inactivated FMDV vaccine and
the FMD VLP at 10 dpi (Figure 2A). All animals in the
two groups showed high neutralization titers after the
vaccine administration. Subsequently, the titers were
further increased and remained at a high level until
challenge (28 dpi), like the specific FMDV antibodies
(Figure 2B). The average levels of the specific and theFigure 2 FMDV-specific immune responses in pigs. Groups of pigs (n =
PBS-inoculated pigs as a control, by intramuscular injection. Blood samples
virus-specific antibody response (A) and neutralizing antibody response (B)
expressed by the average titers of pigs in one whole group at different tim
(C) by PMBC was measured and is shown as pg/mL. Statistical significanceneutralizing antibodies in pigs inoculated with FMD
VLP are similar to those in the group inoculated with
the inactivated FMDV (Figure 2A and B), suggesting
that FMD VLP are competent to induce specific
humoral immune response as the whole FMDV parti-
cles in pigs.
FMDV specific T-cell responses were detected in all
animals vaccinated with both the FMD VLP and the
inactivated FMDV at 28 dpi. Although individual pigs
showed high levels of T-cell response, the average
proliferative responses of all vaccinated pigs did not
show a highly significant increase in the stimulation
indexes, compared with the animals inoculated with
PBS, which was different from the T-cell response in
guinea pigs.
The induction of IFN-γ in PBMC samples from vacci-
nated pigs at day 28 post-vaccination was also determined.
As with the lymphoproliferative responses, secretion of
IFN-γ did not show significant increase in pigs inoculated
with the FMD VLP and the inactivated FMDV, compared
with the PBS control group (Figure 2C). However, the
levels of IFN-γ induction were consistent with the
lymphocyte proliferative responses in individual pigs (data
not shown).
The immunized pigs were challenged with 1000 ID50
FMDV Asia1/China/Jiangsu/2005 per pig at 28 dpi.
Three animals in the PBS control group developed cli-
nical signs of disease on all feet, which remained for se-
veral days. In contrast, none of the animals inoculated
with either the FMD VLP or the FMDV inactivated vac-
cine showed any clinical signs in the mouth and feet.
This confirms that FMD VLP can provide efficient pro-
tection in pigs against FMDV as the conventional
inactivated FMD vaccine.5) immunized with inactivated FMDV or FMD VLP, including three
were collected at 10 dpi, 18 dpi and 28 dpi after vaccination for
. The titers of virus-specific antibody and neutralizing antibody were
e points. PMBC were isolated from all pigs at 28 dpi. IFN-γ secretion
among groups was compared.
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responses in cattle
The potency of the immunity induced by the FMD VLP
in cattle was evaluated as recommended in the OIE
manual [50]. Three groups of cattle were inoculated with
one dose, 1/3 dose and 1/9 dose of FMD VLP, and
LPBE-antibody titers were determined at 9, 16, 21 dpi
and 2, 5, 8, 10 dpc, respectively. All animals vaccinated
with FMD VLP developed a detectable, dose-dependent
FMDV-antibody response at 9 dpi, which reached to a
higher level at 16 dpi (Figure 3A). By 21 dpi, the antibody
levels were either maintained at the same level in the
groups inoculated with one and 1/9 dose, or slightly
increased in the group inoculated with a 1/3 dose
(Figure 3A). Throughout this period, the antibody levels
in the healthy control group remained low (Figure 3A).
Except in cattle inoculated with one full dose of FMD
VLP (which shows a slight increase of the antibody titer
after challenge), drastic induction of specific antibody re-
sponses was observed in all other three groups of cattle
after challenge at 8 and 10 dpc (Figure 3A).
Similar patterns in serum neutralizing antibody re-
sponses were also observed. As shown in Figure 3B, the
neutralizing antibody response in the group of cattle
vaccinated with one dose of FMD VLP was significantly
higher than that in cattle inoculated with 1/3 or 1/9 dose
of FMD VLP, and a gradual increase of neutralizing anti-
body response over time was observed in most vacci-
nated cattle (Figure 3B). Following challenge, the
neutralizing antibody titers in cattle inoculated with
one dose of FMD VLP remained at the same high
level, while a rapid serum-conversion was evident in
the other three groups of animals vaccinated with 1/3
dose, 1/9 dose and healthy control at 8 dpc, respect-
ively (Figure 3B). However, there was no statistically
significant difference in titers for all the treatment
groups by 10 dpc (Figure 3B). This result was in
agreement with the LPBE-antibody titers in cattle.Figure 3 FMDV-specific immune responses in cattle. Groups of cattle (n
including two healthy cattle as the control, by intramuscular injection. Bloo
10 dpc for virus-specific antibody response (A) and neutralizing antibody re
antibody were expressed by the average titer of cattle in one whole group
IFN-γ secretion (C) by PMBC was measured and shown as pg/mL. StatisticaDose-dependent lymphoproliferation responses were
detected in all groups vaccinated with FMD VLP; how-
ever, only animals in the group inoculated with one dose
and 1/3 dose of FMD VLP displayed an increase in
T-cell response, compared with the healthy control
(data were not shown). Similarly, the production of
IFN-γ in PMBC from vaccinated cattle at 21 dpi also
displayed a significant dose-dependent induction pat-
tern, compared with the healthy control (p < 0.05)
(Figure 3C).
Detailed evaluation of the protection potency of FMD
VLP in cattle
Animals in all groups described above were challenged
by intradermal inoculation at two sites in the tongue
with 10 000 ID50 FMDV Asia1/Jiangsu/China/2005 at 21
dpi. Both animals in the control group developed lesions
at secondary sites of replication, including the feet, and
more severe disease was seen by 2–10 dpc. All animals
inoculated with one dose of FMD VLP developed a
vesicle at the sites of injection only. The vesicle was self-
limited and did not increase after 2 dpc. In the group
inoculated with 1/3 dose of FMD VLP, one animal deve-
loped a delayed lesion, which was detectable by 4 dpc
and was present on one foot. Three animals in the group
inoculated with 1/9 dose of FMD VLP developed lesions
beyond the injection sites (Figure 4).
Viremia was evaluated in all animals by determination
of the infectivity (PFUs/mL) and the FMDV RNA levels
in sera. The control animals (#4580, #4576) developed
viremia at day 1 dpc which then lasted for 5 days
(Figure 4). Cattle in the group inoculated with one dose
of FMD VLP induced strong adaptive immune response,
which conferred potent protection against challenge
with FMDV serotype Asia1 and limited the replication of
FMDV in the challenged animals. No viremia was
detected in this group of animals, both by the plaque
assay and by real time RT-PCT (Figure 4). Viremia was= 5) immunized with one dose, 1/3 dose, 1/9 dose of FMD VLP,
d samples were collected at 9 dpi, 16 dpi, 21 dpi and 2 dpc, 5 dpc,
sponse (B). The titers of virus-specific antibody and neutralizing
at different time points. PMBC were isolated from all cattle at 21 dpi.
l significance among groups was compared.
Figure 4 The clinical outcome of cattle challenged with FMDV. Cattle treated with one dose, 1/3 dose, 1/9 dose of FMD VLP and healthy
cattle as control were challenged with 10 000 ID50 of FMDV Asia1/Jiangsu/China/2005 at 21 dpi. The animals were carefully examined in the
muzzle, inside the mouth and feet every day for 10 days after challenge with the homogenous virus. A clinical score of 0 to 5 (right Y axis) was
assigned to describe the severity of the disease, with a maximal score of 5: a score of 0 was assigned when one or more vesicular lesions were
detected at the site of injection on the tongue; a score of 1 was assigned when one or more vesicular lesions were detected in the mouth other
than the tongue; a score of 2 was assigned when one or more vesicular lesions were detected in one foot, a score of 3 was assigned if two feet
had vesicular lesions, a score of 4 was assigned if three feet had vesicular lesions, a score of 5 was assigned if four feet had vesicular lesions.
Animals showing viremia were selected and listed. The maximum clinical score (bars) is 5. Viremia (left Y axis) determined by infectivity and viral
RNA level are expressed as log10 PFU/mL and log10 copies/mL respectively.
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of FMD VLP, but not detected in other animals in the
group (Figure 4). All the animals inoculated with 1/9
dose of FMD VLP developed viremia, as detected by a
plaque assay and confirmed by real-time RT-PCR, al-
though one animal in this group did not show lesions
(Figure 4). The onset of viremia in all animals in this
group was delayed and the viremia lasted for a shorter
period of time. The copies of FMDV RNA molecules
were generally 103- to 105-fold lower than in the control
animals (Figure 4).
The PD50 test was then performed to assess the subunit
vaccine potency following the bovine potency test proto-
col for traditional inactivated FMD vaccines described by
the OIE. The result shows that the vaccine potency of the
batch immunized with the FMD VLP reached 6.34 PD50
per dose, which was higher than that for routine prophy-
lactic use and also meets the requirement for emergency
(“ring”) vaccination as specified by OIE (Table 1).
Efficient induction of antibody responses by FMD VLP
against the three structural proteins
Sera from animals vaccinated with the FMD VLP and
the inactivated FMDV vaccine were finally assessed by
Western blot to investigate if all three structural proteins
used to prepare the VLP are immunogenic. For this pur-
pose, total cell lysates were prepared from FMDV-
infected BHK-21 cells and analyzed by Western blot.
The results show that sera collected from all three ani-
mal species vaccinated with FMD VLP could efficientlyreact with the three proteins from both virus-infected
cells and FMD VLP preparation (Figure 5). Moreover,
similar patterns and efficiencies of the reaction were ob-
served from animal sera vaccinated with the inactivated
FMDV (Figure 5). These results demonstrate that all
three structural proteins are equally antigenic, although
they are expressed and purified from a prokaryotic ex-
pression system, and further suggest that these proteins
may be incorporated and assembled into VLP with an
equal efficiency as well as in a correct conformation.
Discussion
In this study, we attempt to produce the FMD VLP
in E. coli and use this VLP preparation as a vaccine
candidate for the first time to characterize the im-
munological properties in a laboratory animal model
and in two natural FMDV host animal species, swine
and cattle.
The three SUMO fusion proteins were shown to form
stable VLP with size and shape resembling the native
FMDV particles, upon simultaneous expression and
removal of the SUMO moiety from the SUMO-fusion
proteins. The SUMO-fusion system with modification
provides increased levels of expression of FMDV capsid
proteins in E. coli and allows rapid purification of target
proteins, by exploiting the properties that SUMO fused
at the N-terminus with other proteins can fold and pro-
tect the protein by its chaperoning properties. The
results of this study demonstrate that SUMO-fusion dra-
matically enhances the expression of the FMDV capsid
Figure 5 Specificity of animal serum against whole FMDV and
VLP. The purified FMD VLP (about 0.1 μg) and total cell lysates
prepared BHK-21 cells infected with mock or FMDV were separated
by SDS-PAGE, and analyzed by Western blot with sera from cattle,
pig and guinea pig unvaccinated or vaccinated with inactivated
FMDV or FMD VLP being used as primary antibodies.
Table 1 The neutralizing titer, T-lymphocyte proliferation and protection of cattle
Group No Neutralizing titer T-lymphocyte proliferation (SI) Protection Rate of protection PD50
9 dpi 16 dpi 21 dpi 21 dpi 10 dpc
One dose #4536 2.408 2.709 2.107 1.989 yes 100(5/5) 6.34
#4572 2.107 2.408 2.408 1.602 yes
#4574 2.408 2.709 2.107 1.373 yes
#4590 2.107 2.408 2.408 1.586 yes
#4592 2.408 2.709 2.408 1.625 yes
1/3 dose #4501 1.806 1.806 1.806 1.587 yes 80(4/5)
#4561 1.204 1.505 1.806 1.512 yes
#4575 1.806 2.107 2.107 1.721 yes
#4593 1.806 1.806 1.806 1.889 yes
#4597 1.204 1.204 1.505 1.353 no
1/9 dose #4534 1.505 1.505 1.806 1.351 no 40(2/5)
#4563 1.505 1.505 1.204 1.886 yes
#4564 1.204 1.505 1.505 1.375 no
#4594 1.806 1.806 1.806 1.558 yes
#4598 1.204 1.505 1.505 1.397 no
Healthy cattle #4576 0.778 0.903 0.778 1.052 no 0(0/5)
#4580 0.903 0.778 0.602 1.115 no
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bly. Although it is not fully understood why SUMO
fusion can enhance the protein solubility, structural
studies suggest that SUMO has an external hydrophilic
surface and inner hydrophobic core, which may exert a
detergent-like effect on otherwise insoluble proteins
[30]. The next question would be whether the immuno-
genicity of these VLP is also similar to the FMDV native
virions. Our results indicate that the FMD VLP could in-
duce specific antibody responses against whole FMDV
virions in guinea pigs, swine and cattle, as demonstrated
by indirect ELISA, LPB-ELISA and Western blot ana-
lyses. This suggests that the three proteins expressed
and purified from E. coli are properly folded in the VLP.
In addition, the data available from mapping of the neu-
tralizing antibody epitopes in serotype O, the most
extensively studied FMDV [51,52] and in Asia 1 by
Butchaiah and Morgan [53] demonstrate that the major
immunologic epitopes of serotype Asia 1 are on the sur-
face oriented interconnecting loops between structural
elements. Our observation that potent neutralizing anti-
body responses were induced by FMD VLP in all three
vaccinated animal species demonstrates that the three
proteins were not only correctly assembled into VLP but
the neutralizing epitopes were also presented correctly
on the surface of virus capsids. Further confirmation
of the neutralizing epitopes of FMDV Asia1 together
with crystallographic studies to identify the structure
of the FMDV capsids would provide more insight into
these issues.
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detection of specific antibodies against whole FMDV in
sera from guinea pigs, pigs and cattle. Interestingly, the
specific antibody titers in animals vaccinated with FMD
VLP, as determined by indirect-ELISA and LPB-ELISA,
showed a good correlation with the neutralization titers,
which was consistent with the results reported previ-
ously [54,55]. Meanwhile, a good correlation between
specific antibody titers and protection was also observed
in this study.
Virus-induced neutralizing antibody response is crucial
for the development of protection against FMD. A nice
correlation between the neutralizing antibody titers and
the levels of protection against live virus challenge has
been found in many studies [56-58]. Similarly, neutrali-
zing antibody responses in guinea pigs, pigs and cattle
inoculated with either one or 1/3 dose of the FMD VLP
were shown in this study to have a positive correlation
with protection against FMDV challenge. However, at
21 days post vaccination (pre-challenge) in cattle, one of
the animals (#4563) inoculated with 1/9 dose of FMD VLP
was shown to have an antibody titer lower than the thres-
hold titer, but showed resistance to challenge; whereas
another one (#4534) with a higher titer did not. This
may suggest that the correlation between virus neutra-
lization titer and protection could mainly depend on the
dose of FMD VLP used in addition to the possibility of
an individual variation in resistance to infection by the
virus. This correlation may be proportional within a cer-
tain range of dosage. If the dose is too low, no corre-
lation between virus neutralization titer and protection
would be observed, as in the case when cattle were vac-
cinated with 1/9 dose of VLP (#4563 and #4534). Other
factors, including batch and strain of FMD vaccine used,
the route of inoculation, the virus titer for challenge,
and so on, could also affect the correlation between the
protection rate and the specific antibody/neutralizing
antibody titer.
Certain non-antibody-mediated immune mechanisms,
such as T-cell activation and the cytokines they release,
may also play a role [59]. The results of T lymphocyte
proliferation response and cytokine release in animals
vaccinated in this study suggest that 50 μg FMD VLP is
enough to induce the T-lymphocyte proliferation re-
sponse and induction of IFN-γ in the guinea pig, pig and
cattle. When the dose is too low to induce sufficient
protective neutralizing titers, the T-cell response would
promote protection against the virus infection initially
provided by neutralizing antibodies. Although the T-cell
response and IFN-γ secretion in pigs and cattle did not
increase as significantly as shown in guinea pigs, a cor-
relation between T-cell response and IFN-γ secretion
was observed in all vaccinated animals. It is assumed
that optimal IFN-γ production requires the inclusion ofan efficient T-cell epitope in a suitable configuration.
IFN-γ is a major activator of macrophages, enhancing
their antimicrobial activity and their capacity for pro-
cessing and presenting antigens to T lymphocytes [60].
It has been reported that IFN-γ stimulates MHC expres-
sion in antigen-presenting cells and efficiently inhibits
FMDV replication [61]. Therefore, better clinical protec-
tion conferred by the FMD VLP in this study, especially
when no sufficient neutralizing antibody response was
elicited, would be due to an efficient lymphoproliferative
response and IFN-γ release. Further biochemical studies
are required to understand the cooperative, redundant,
or synergistic effects in the antiviral properties of T-cell
response and this cytokine induced by FMD VLP.
The development of lesions and viremia in FMD VLP-
inoculated cattle challenged with FMDV appears to fol-
low a dose-dependent response pattern. One dose of the
50 μg FMD VLP efficiently prevented the development
of disease, when the animals were exposed to the virus
by direct inoculation in the epithelia of the tongue as
recommended by the OIE in efficacy testing [50]. Most
animals (4/5) treated with 1/3 dose of FMD VLP also
did not develop lesions; only one animal in this group
with a lower neutralizing antibody response showed mild
lesions and short-lived viremia. Two animals vaccinated
with 1/9 dose of FMD VLP had a slight delay in the ap-
pearance of viremia and development of the disease,
compared to the control animals. In general, a good cor-
relation between the development of viremia and the
neutralizing antibody response was observed after
FMDV challenge within the groups of cattle.
The PD50 value of the VLP vaccine is calculated from
the number of cattle protected in each group. According
to the OIE manual [50], when employed for routine
prophylactic use, the FMD vaccine should contain at least
3 PD50 per dose for cattle. But for emergency vaccination,
it should have 6 PD50 per dose for cattle. In our study,
the FMD VLP contain 6.43 PD50 per dose for cattle, illus-
trating the potency of FMD VLP as a potential emergency
vaccine. On the contrary, FMD VLP can prevent the
development of local tongue lesions at the site of chal-
lenge, indicating high potency of FMD VLP as one of
the vaccine formats. In addition, since potency resulting
from cattle tests can be a good indicator for the vaccine
applicability in other species, the potency of FMD VLP
could be sufficient to endorse its use in pigs, which is
the reason why the potency test in swine was not car-
ried out.
Taken together, our present results show the potential
of using FMD VLP produced in E. coli as a vaccine can-
didate. Vaccination with a single injection of 50 μg of
proteins could elicit a high level of immune response,
which is sufficient to protect guinea pigs, swine and cat-
tle from virulent virus infection.
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